Search results
Op-ed: Here are 6 health-care stocks to watch now, amid a bumpy recovery
CNBC· 13 hours agoHealth care, long an ailing stock market sector, has recovered over the past six months, with...
20 30-Minute Mediterranean Diet Dinners for Spring
Eating Well via Yahoo News· 2 days agoShe created this recipe for Lemongrass-&-Coconut Poached Salmon exclusively for EatingWell. It features a trifecta of inflammation-fighting...
UBS Group Trims Amgen (NASDAQ:AMGN) Target Price to $284.00
ETF DAILY NEWS· 5 days agoAmgen (NASDAQ:AMGN – Free Report) had its price objective trimmed by UBS Group from $314.00 to $284.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently ...
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar | JD Supra
JD Supra· 2 days agoOn April 16, Alvotech and Teva announced the FDA approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Johnson and Johnson’s STELERA® (ustekinumab). The product was approved as a subcutaneous ...
Is Sleeping on Your Stomach Bad for You? Experts Weigh in on Which Mattress Is Best
Prevention via Yahoo News· 2 days agoExperts say the best mattresses for stomach sleepers offer medium-firm support, cradle hips and...
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 1 day agoThese product candidates are being developed to treat patients with graft-versus-host disease, psoriatic arthritis, alpha-1-antitrypsin deficiency,...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 2 days agoOctober 2023, the FDA approved Cosentyx for treating moderate-to-severe hidradenitis suppurativa...
What Are the Most Effective Psoriasis Therapy Options?
Verywell Health via Yahoo News· 24 hours agoWith many treatment options for psoriasis, how do you know which ones are right for you? Here are...
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Zacks via Yahoo Finance· 5 days agoRinvoq is already approved to treat several autoimmune diseases like rheumatoid arthritis, psoriatic...
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant...
NBC 17 Raleigh· 7 days ago− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen ...